RxDoctor Payments Data

Jonathan Rhodes, NP

Psychiatric/Mental Health · Aberdeen, NJNPI 1477062800

Payments from drug & device makers

$1,662in general payments, 2019–2025

Across 108 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$729
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$167
  • Johnson & Johnson$147
  • Novartis$106
  • Teva Pharmaceuticals USA, Inc.$93
  • Indivior Inc.$93
  • plus $327 from 11 others

What the payments were for

  • Food & beverage$1,58495%
  • Education$785%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,662 in reported general payments places this provider in the 75th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$14,395
Medicare patients
33
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate119$343,716
VivitrolNaltrexone Microspheres14$24,566
RexultiBrexpiprazole17$24,555
VraylarCariprazine Hcl11$14,908
Aripiprazole93$8,948
Paliperidone ErPaliperidone50$8,930
Quetiapine Fumarate112$7,011
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$6,140
Clozapine80$5,857
VyvanseLisdexamfetamine Dimesylate14$5,614
Asenapine Maleate12$5,305
Olanzapine154$4,129
Fluvoxamine Maleate73$3,683
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl24$3,283
Duloxetine Hcl70$2,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$147$343,716119 claims
Alkermes, Inc.Vivitrol$53$24,56614 claims
Otsuka America Pharmaceutical, Inc.Rexulti$52$24,55517 claims
AbbVieVraylar$729$14,90811 claims
Indivior Inc.Suboxone$93$6,14011 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$26$5,61414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Aberdeen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →